Friday, July 11, 2025 3:09:11 PM
Yesterday, among other perplexing comments, you wrote in reference to Mayo/Roswell pooled tumor lysate trials with Merck:
The product in question might not be separate at all (from our DCVax products). It may be the same architecture, the same immune engine, just stripped of its autologous tumor input. Who is behind it has not been named, (NWB?) but the blueprint is unmistakable.
Then you went on to write about the Merck trials:
Several trials sponsored by Roswell Park or Kalinski’s lab have combined dendritic cell vaccines with checkpoint inhibitors like pembrolizumab. These include studies in colorectal cancer, head and neck cancer, and solid tumors, with Merck often providing drug or in-kind support. The protocols are structurally similar to DCVax-Direct, using antigen loaded dendritic cells matured under Kalinski’s patented cytokine conditions. That intellectual property belongs to Roswell Park and remains exclusively licensed to Northwest Biotherapeutics.
Then today you said unequivocally:
The company (NWBO) holds the rights to a specific method combining pooled tumor lysate with autologous dendritic cells to induce immune responses against solid tumors. That is the approach Mayo studied, Mill Creek manufactured, and NWBO controls under its license.
Taken together, the data, funding, and regulatory position suggest that while development occurred across institutions, the underlying platform method remains within NWBO’s IP framework.
So, my final question is: If it's true that Merck is testing it's Keytruda with NWBO's in-licenced DC products from Roswell, are they plotting to get ahead of us or planning to partner with us? I'm not actually asking you to make a wild guess, so much as an educated one, based on the facts.
Thanks, Slave1! Have a great weekend!
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
